drugset / Trial / NCT00812331

A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)

NCT00812331

Phase 2 Completed 37 enrolled Tibotec Pharmaceuticals, Ireland
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess anti-viral activity (inhibition of viral growth) of TMC435350 in genotype 2,3,4,5 and 6 hepatitis C virus infected participants who have never received treatment for their hepatitis C infection.

Timeline

Start
2009-03
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Simeprevir Small molecule 200 mg Oral